Effect of Dupilumab on Sleep Apnea in Patients With Rhinosinusitis
Status:
Unknown status
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
Obstructive Sleep Apnea (OSA) is a common disorder with serious consequences that remains
underrecognized, with >80% of OSA patients undiagnosed, and undertreated due to inadequate
treatment options. The development of additional treatments for OSA, such as pharmacotherapy,
are critically needed.
The collaboration between Regeneron and Sanofi are funding this project. Regeneron will be
providing the drug and the contract will be with Regeneron. Both companies are involved as it
is a collaboration across the companies.